Baseline albumin-bilirubin (ALBI) in Western patients with hepatocellular carcinoma treated with stereotactic body radiotherapy (SBRT)

In a prospective series of 102 Western patients with Child Pugh A hepatocellular carcinoma (HCC) managed with stereotactic body radiotherapy (SBRT), the baseline albumin-bilirubin (ALBI) score was evaluated as a predictor of survival and hepatic toxicity. ALBI was an independent significant predictor of toxicity and survival, and was more discriminating than Child Pugh score. Thus, ALBI warrants further investigation and should be included as a factor for stratification in future clinical trials.

https://ift.tt/2GQqna6